公开(公告)号：US20240033264A1

公开(公告)日：2024-02-01

申请号：US18373067

申请日：2023-09-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/55 ,  C07D405/14 ,  C07D487/04 ,  A61K45/06 ,  C07D401/14

CPC classification number: A61K31/506 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/55 ,  C07D405/14 ,  C07D487/04 ,  A61K45/06 ,  C07D401/14

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20230382899A1

公开(公告)日：2023-11-30

申请号：US18031380

申请日：2021-10-13

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo ,  Zheng Jane Li ,  Xiawei Jiang ,  Pengyuan Chen

IPC: C07D405/14

CPC classification number: C07D405/14 ,  C07B2200/13

Abstract: Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

公开(公告)号：US20230339896A1

公开(公告)日：2023-10-26

申请号：US18013402

申请日：2021-07-02

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: A61P35/00 ,  C07D401/14

CPC classification number: C07D401/14 ,  A61P35/00

Abstract: The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPKl activity.

公开(公告)号：US20230203023A1

公开(公告)日：2023-06-29

申请号：US17927502

申请日：2021-05-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Meng Jiang ,  Beibei Chen ,  Xudong Wei ,  Wenge Zhong

IPC: C07D405/14 ,  C07C55/22

CPC classification number: C07D405/14 ,  C07C55/22 ,  C07B2200/13

Abstract: Various salt forms of Compound I and Compound II represented by the following structural formulae, and their corresponding pharmaceutical compositions, are disclosed. (I), (II) Particular single crystalline forms of 1:1 Compound I tris salt, 1:1 Compound II tris salt, and 1:1 Compound II citrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

公开(公告)号：US11591321B2

公开(公告)日：2023-02-28

申请号：US16950393

申请日：2020-11-17

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (III) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20220296595A1

公开(公告)日：2022-09-22

申请号：US17608915

申请日：2020-05-05

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Xiaotian Zhu ,  Wenge Zhong

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61P35/00 ,  C07D405/14 ,  C07D487/04

Abstract: Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20200283424A1

公开(公告)日：2020-09-10

申请号：US16874908

申请日：2020-05-15

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong

IPC: C07D405/14 ,  C07D471/04 ,  C07D471/08 ,  C07D498/04

Abstract: The invention described herein provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.